https://www.live-feeds.com/feed/gsk-plans-phase-3-after-mrna-flu-vaccine-beats-standard-shotsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/gsk-plans-phase-3-after-mrna-flu-vaccine-beats-standard-shotshttps://www.live-feeds.com/feed/gsk-plans-phase-3-after-mrna-flu-vaccine-beats-standard-shots#u56680Fri, 04 Sep 2026 07:55:18 +0000GSK is advancing its mRNA influenza vaccine into a Phase III clinical trial utilizing a newer formulation after trial data showed the shot outperformed standard vaccines. The company aims to compete directly against Moderna in the mRNA influenza vaccine market. A Connecticut health official noted that the new shot could provide older adults with better protection against the virus. The upcoming late-stage study follows a successful Phase II trial that demonstrated stronger immune responses and good tolerability for the experimental immunization.Why it mattersTraditional influenza vaccines rely